Trials / Completed
CompletedNCT00109200
A Continued Access Protocol to Provide Xolair to Patients With Severe Allergic Asthma
A Continued Access Protocol to Provide Xolair® (Omalizumab) to Subjects With Severe Allergic Asthma Who Have Received Xolair Treatment in a Previous Investigational Study
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This is a continued access protocol to provide subjects who have completed Genentech, Inc. Study Q2143g, Q2195g, or Q2461g or Novartis Pharmaceuticals Corporation Study CIGE025 0010E1 with continued Xolair treatment. Subject eligibility will be based on disease severity and asthma deterioration upon withdrawal of Xolair treatment. Subjects whose last Xolair dose was \<9 months prior to screening visit will continue with the same Xolair dosing regimen that they received in the previous Genentech or Novartis clinical study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Xolair (omalizumab) |
Timeline
- Start date
- 2003-05-01
- Completion
- 2003-09-01
- First posted
- 2005-04-26
- Last updated
- 2013-06-21
Source: ClinicalTrials.gov record NCT00109200. Inclusion in this directory is not an endorsement.